FENNEC PHARMACEUTICALS Business Summary

Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company that generates revenue primarily through the direct sale of its flagship product, PEDMARK (sodium thiosulfate injection), marketed as PEDMARQSI in Europe and the United Kingdom. The company operates as a single-segment entity focused on oncology supportive care, specifically the prevention of cisplatin-induced ototoxicity (permanent hearing loss) in pediatric patients with localized, non-metastatic solid tumors. As of early 2026, Fennec holds a unique market position as the provider of the first and only FDA- and EMA-approved therapy for this indication, maintaining a significant competitive moat with no direct therapeutic rivals. Its primary competitors in the broader pediatric oncology and supportive care markets include Y-mAbs Therapeutics, Day One Biopharmaceuticals, and Amgen, though Fennec distinguishes itself through its specialized orphan drug status and expansion into the adolescent and young adult (AYA) patient populations. The company is led by Chief Executive Officer Jeff Hackman, who assumed the role in August 2024 following a successful tenure as CEO of Comera Life Sciences and senior leadership positions at EUSA Pharma, Shire, and Baxalta. The executive team was significantly bolstered in late 2024 with the appointments of Dr. Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer, all of whom bring extensive oncology commercialization expertise. The Board of Directors is chaired by Dr. Khalid Islam, the former CEO of Gentium S.p.A., and includes long-time former CEO Rostislav Raykov, who transitioned to a director role after leading the company for 15 years. Fennec maintains strong institutional support from major investors including Southpoint Capital Advisors, Rosalind Advisors, and Eshelman Ventures, the investment vehicle of pharmaceutical industry veteran Fredric Eshelman.